FR-Rouen cedex-BECQUEREL
Welcome,         Profile    Billing    Logout  
 3 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LEMASLE, Emilie
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
OGILAR, NCT06022003: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Recruiting
2
33
Europe
AzaCITIDine Oral Tablet, Onureg, CC-486, Xospata, Gilteritinib
French Innovative Leukemia Organisation, Acute Leukemia French Association
AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD
10/26
10/27
AGORA-1, NCT05199051 / 2021-001813-35: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML

Recruiting
2
50
Europe
Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata
Centre Antoine Lacassagne, Acute Leukemia French Association, Astellas Pharma Inc, Pfizer
AML
03/27
03/27
SALMA, NCT05580861: Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

Recruiting
1/2
64
Europe
Sulfasalazine
Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia
11/25
12/26
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting
N/A
2500
Europe
Acute Leukemia French Association
Acute Myeloid Leukemia (AML)
04/32
04/46
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

Recruiting
N/A
230
Europe
French Innovative Leukemia Organisation, Acute Leukemia French Association
AML, Adult
12/24
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LEMASLE, Emilie
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
OGILAR, NCT06022003: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Recruiting
2
33
Europe
AzaCITIDine Oral Tablet, Onureg, CC-486, Xospata, Gilteritinib
French Innovative Leukemia Organisation, Acute Leukemia French Association
AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD
10/26
10/27
AGORA-1, NCT05199051 / 2021-001813-35: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML

Recruiting
2
50
Europe
Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata
Centre Antoine Lacassagne, Acute Leukemia French Association, Astellas Pharma Inc, Pfizer
AML
03/27
03/27
SALMA, NCT05580861: Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

Recruiting
1/2
64
Europe
Sulfasalazine
Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia
11/25
12/26
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting
N/A
2500
Europe
Acute Leukemia French Association
Acute Myeloid Leukemia (AML)
04/32
04/46
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

Recruiting
N/A
230
Europe
French Innovative Leukemia Organisation, Acute Leukemia French Association
AML, Adult
12/24
03/25

Download Options